CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 86 enrolled
Drug / intervention
The Lifestar Act IIIdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02743520
NCT02743520N/ACompleted

Early Identification of Patients With Coexisting Atrial Fibrillation and Obstructive Sleep Apnea

University of Miami·interventional·Posted Apr 19, 2016·Updated Nov 19, 2020

In Brief

A clinical study evaluating The Lifestar Act III for Atrial Fibrillation and 2 related conditions. Completed, enrolled 86 participants across 1 site.

Detailed Summary

The purpose of this research study is to learn about arrhythmia detection in obstructive sleep apnea (OSA). For several years patients with OSA have an increased likelihood of having irregular heartbeats. This study will determine how often patients with OSA have irregular heartbeats. This study will also define which OSA patients are most likely to have irregular heartbeats. The participant is being asked to be in the study because the participant has been diagnosed with obstructive sleep apnea (OSA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedApr 19, 2016
Enrollment StartMar 6, 2017
Primary CompletionApr 3, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.2 years ago

Interventions

The Lifestar Act IIIdevice

The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.